Quark Becomes Latest RNAi Drug Developer To Score Big Pharma Support With Pfizer Deal
Quark Becomes Latest RNAi Drug Developer To Score Big Pharma Support With Pfizer Deal
By Doug Macron
September 28, 2006
RNAi News
Under the deal, Pfizer has acquired an exclusive license to RTP-801, Quark?s proprietary gene target associated with numerous diseases, as well as the company?s investigational siRNA-based treatment for age-related macular degeneration.
Paid subscription is required to view article.
Votes:3
Comments: 0